



October 17, 2025

To,  
The Manager  
Listing Department,  
**The National Stock Exchange of India Limited**  
Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051

Dear Sir/Madam,

**Trading Symbol: ZOTA**

**Sub: Press Release on Unaudited Financial Results for the quarter and half year ended September 30, 2025**

With reference to the captioned subject; we, Zota Health Care Limited are forwarding herewith enclosed a copy of press release on Unaudited Financial Results for the quarter and half year ended September 30, 2025.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Zota Health Care Limited**

**Ashvin Variya**  
**(Company Secretary & Compliance Officer)**  
**Place: Surat**

Encl: Press Release

**Registered Office:**

Zota House, 2/896, Hira Modi Street,  
Sagrampura, Surat-395002 Ph: +91 261 2331601  
Email: [info@zotahealthcare.com](mailto:info@zotahealthcare.com)  
Web: [www.zotahealthcare.com](http://www.zotahealthcare.com)

CIN: L24231GJ2000PLC038352

### Zota Health Care Limited Delivers Strong Q2FY26 Performance with 92% YoY Consolidated Revenue Growth

*Q2FY26 Consolidated Revenues Grew to ₹ 12,895 lakhs: EBITDA at ₹ 796 lakhs.*

*DavaIndia Networks Expands to 2,055 Stores Nationwide*

**Surat, 17<sup>th</sup> October 2025:**

Zota Health Care Limited, one of the leading pharmaceutical companies with an aim is to provide affordable, high-quality, generic medicines predominantly for chronic conditions, in addition to proprietary medicinal, OTC, ayurvedic, cosmetic, and nutraceutical products, announced financial results for the Second Quarter and Half year ended 30<sup>th</sup> September 2025.

#### Q2FY26 Business Highlights:

Particulars	Q2FY26			Q2FY25		
	COCO	FOFO	Total	COCO	FOFO	Total
Total No. of DavaIndia stores*	1,207	848	2,055	501	664	1,165
Quarterly Footfall (lakhs)	29.62	13.91	43.53	11.84	10.39	22.23
Quarterly GMV (₹ lakhs)	6,780	3,923	10,703	2,714	2,840	5,554
Average wallets spend (₹)	229	282	-	229	274	-

*As on 30<sup>th</sup> September 2025*

#### Key Operational & Financial Highlights:

- Consolidated Revenue from operation stood at ₹ 12,895 lakhs in Q2FY26 an significant increase of 92% YoY from ₹ 6,728 lakhs in Q2FY25.
- Consolidated Gross Profit stood at ₹ 7,650 lakhs compared to ₹ 3,602 lakhs during Q2FY25, a significant increase of 112%.
- Consolidated EBITDA turned positive straight for the second quarter at ₹ 796 lakhs in Q2FY26.
- Added 310 new stores during Q2FY26 with 221 COCO & 89 FOFO stores.
- DavaIndia Networks Expands to 2,055 Stores Nationwide.
- Zota Group Appoints Cricketing Legend Mahendra Singh Dhoni followed by Suniel Shetty as Brand Ambassador of DAVAINDIA to further strengthen the brand's visibility and outreach.

#### Commenting on the Q1FY26 performance, Mr. Ketan Kumar Zota, Chairman, Zota Health Care Limited said,

*"We are pleased to report another strong quarter driven by robust operational execution and strategic expansion taking our total store count to 2,055. This includes 1,207 COCO and 848 FOFO outlets as on 30<sup>th</sup> September 2025. The rapid expansion, especially in COCO format, is not just about scale but about deepening access to affordable, quality generic medicines across India.*

*We delivered an impressive 92% year-on-year consolidated revenue growth in Q2FY26 supported by our strategic expansion. EBITDA reached ₹796 lakhs. Quarterly footfalls more than doubled to 43.53 lakhs, up from 22.23 lakhs in Q2 FY25. This surge in footfall translated into a 91% increase in (GMV), which rose to ₹10,703 lakhs from ₹ 5,554 lakhs in the same period last year.*

*To fuel ongoing growth, the Board has approved a fund-raising proposal of up to ₹500 crore through Qualified Institutional Placement. This will help us accelerate our store expansion and drive business scalability. Our brand continues to gain strong visibility, with M.S. Dhoni joining as the brand ambassador for DavaIndia, following Suniel Shetty, reinforcing our commitment to credibility and trust. In line with our backward integration strategy, we increased our stake in Everyday Herbal Beauty Care Pvt. Ltd. by 9.98%, raising our total holding to 65.98%, which further strengthens our OTC product portfolio.*

*Looking ahead, we remain committed to driving sustainable growth by expanding our national footprint, enhancing store-level efficiencies, and staying aligned with the evolving needs of the Indian generics market."*

**About Zota Health Care Limited:**

Zota Health Care Ltd. (Zota), listed on the NSE, has been a key player in the Indian healthcare industry since 2000. Headquartered in Surat, Zota's team of over 520 professionals drives its growth and strong market presence. The company specializes in the development, manufacturing, and marketing of high-quality pharmaceutical, ayurvedic, nutraceutical, and over-the-counter products.

Zota operates through three main divisions: marketing, export, and the retail pharmacy chain. In 2017, Zota launched Davaindia, a generic pharmacy chain offering over 2,000 SKUs of quality medicines. Davaindia's strategic business model ensures efficient management of the entire product life cycle through backward and forward integration.

Zota is renowned for its innovative Research and Development team, consistently investing in pioneering healthcare solutions, reinforcing its reputation in the industry. For more information, visit: [www.zotahealthcare.com](http://www.zotahealthcare.com)

**For details please contact:**

<b>Mr. Ashvin Variya</b>	<b>Mr. Siddesh Chawan</b>	<b>Mr. Ajit Mishra</b>
CS, Zota Health Care Ltd	Ernst & Young LLP, Investor Relations	Ernst & Young LLP, Investor Relations
E: <a href="mailto:cszota@zotahealthcare.com">cszota@zotahealthcare.com</a>	E: <a href="mailto:Siddesh.Chawan@in.ey.com">Siddesh.Chawan@in.ey.com</a>	E: <a href="mailto:Ajit.J.Mishra@in.ey.com">Ajit.J.Mishra@in.ey.com</a>

***Disclaimer:** Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political, or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Zota Health Care Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*